| scholarly article | Q13442814 |
| P2093 | author name string | Jérôme Fayette | |
| Max Gau | |||
| Andy Karabajakian | |||
| Eve-Marie Neidhardt | |||
| Thibault Reverdy | |||
| P2860 | cites work | Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States | Q22306233 |
| Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases. | Q53017314 | ||
| Induction chemotherapy before surgery for unresectable head and neck cancer. | Q53118432 | ||
| Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial | Q56958268 | ||
| A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in p | Q58903143 | ||
| Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis | Q82615896 | ||
| GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma | Q87519991 | ||
| Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial | Q90280098 | ||
| Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma | Q26782499 | ||
| Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. | Q30654037 | ||
| Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer | Q33377142 | ||
| Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer | Q34106818 | ||
| Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323 | Q34255935 | ||
| Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial | Q34328071 | ||
| Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer | Q34430205 | ||
| Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer | Q34477841 | ||
| Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Q34620650 | ||
| Analysis of the prognostic factors for distant metastasis after induction chemotherapy followed by concurrent chemoradiotherapy for head and neck cancer | Q34977200 | ||
| Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study | Q35602143 | ||
| Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study | Q35793403 | ||
| A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer | Q36116366 | ||
| Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer | Q36625201 | ||
| Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy | Q37300034 | ||
| Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients | Q37392967 | ||
| Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study | Q38787080 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. | Q40126687 | ||
| Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients | Q43681440 | ||
| Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study | Q43772035 | ||
| A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer | Q43821393 | ||
| Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. | Q45152760 | ||
| Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. | Q45366580 | ||
| Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. | Q46036998 | ||
| Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer | Q46932585 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| de-escalation | Q1182511 | ||
| head and neck squamous cell carcinoma | Q18348812 | ||
| P304 | page(s) | 15 | |
| P577 | publication date | 2018-12-22 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief | |
| P478 | volume | 11 |
| Q89967045 | Systemic Analysis of RNA Alternative Splicing Signals Related to the Prognosis for Head and Neck Squamous Cell Carcinoma | cites work | P2860 |
Search more.